Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:I-16-I-23
doi: 10.1161/CIRCULATIONAHA.106.679688
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yildirim, Y.
Right arrow Articles by Zimmermann, W.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yildirim, Y.
Right arrow Articles by Zimmermann, W.-H.
Related Collections
Right arrow Contractile function
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy
Right arrow CV surgery: other

(Circulation. 2007;116:I-16 – I-23.)
© 2007 American Heart Association, Inc.


Cardiac Transplantation and Surgery for Heart Failure

Development of a Biological Ventricular Assist Device

Preliminary Data From a Small Animal Model

Yalin Yildirim, BS*; Hiroshi Naito, MD*; Michael Didié, MD; Bijoy Chandapillai Karikkineth, MD; Daniel Biermann, BS; Thomas Eschenhagen, MD; Wolfram-Hubertus Zimmermann, MD

From the Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany.

Correspondence to Wolfram-Hubertus Zimmermann, MD, Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. E-mail w.zimmermann{at}uke.uni-hamburg.de

Background— Engineered heart tissue (EHT) can be generated from cardiomyocytes and extracellular matrix proteins and used to repair local heart muscle defects in vivo. Here, we hypothesized that pouch-like heart muscle constructs can be generated by using a novel EHT-casting technology and applied as heart-embracing cardiac grafts in vivo.

Methods and Results— Pouch-like EHTs (inner/outer diameter: 10/12 mm) can be generated mainly from neonatal rat heart cells, collagen type I, and serum containing culture medium. They contain a dense network of connexin 43 interconnected cardiomyocytes and an endo-/epicardial surface lining composed of prolylhydroxylase positive cells. Pouch-like EHTs beat spontaneously and show contractile properties of native heart muscle including positive inotropic responses to calcium and isoprenaline. First implantation studies indicate that pouch-like EHTs can be slipped over uninjured adult rat hearts to completely cover the left and right ventricles. Fourteen days after implantation, EHT-grafts stably covered the epicardial surface of the respective hearts. Engrafted EHTs were composed of matrix and differentiated cardiac muscle as well as newly formed vessels which were partly donor-derived.

Conclusions— Pouch-like EHTs can be generated with structural and functional properties of native myocardium. Implantation studies demonstrated their applicability as cardiac muscle grafts, setting the stage for an evaluation of EHT-pouches as biological ventricular assist devices in vivo.


Key Words: tissue engineering • myocardium • cardiomyocyte • regeneration • transplantation